46 results about "Childbearing age" patented technology

The invention discloses a recoverable umbrella-shaped fallopian tube intrauterine device. The intrauterine device comprises a tube body. The top end of the head of the tube body is provided with an agnail which is of an umbrella-shaped structure. The end of the tube body is provided with a ring body which is of a flat-shaped hollow structure. The ring body is provided with a through hole. A barb and calabash-like protrusions are arranged between the agnail and the ring body. The agnail, the barb, the calabash-like protrusions, the ring body and the tube body are of an integrated structure. A conveyor is a medical plastic catheter. The recoverable umbrella-shaped fallopian tube intrauterine device is reasonable in structure and design. Due to the fact that the intrauterine device is manufactured by using the integrated structure and high molecular materials, the intrauterine device is safe and reliable, the occurrence of salpingitis after placing the device is decreased, and the effectiveness of blocking the fallopian tube after placing the device is guaranteed. Together with other contraception measures, the intrauterine device can be used for the contraceptive operation on women of childbearing age. The intrauterine device has the advantages of being free from surgery and pain, and convenient to operate. The intrauterine device is an efficient, safe, non-toxic, deformity free, non-carcinogenic, reversible and complication free contraceptive tool and is acceptable by most of the women of childbearing age.

Beneficiaries are registered by an insurance provider for an insurance coverage policy for fertility diagnosis and treatable infertility conditions using either manual or online registration applications over a communications network. Using, knowledge base systems, prospective beneficiary personal descriptor information is matched with terms and conditions information preloaded into the insurance company computer system to generate a customized contract for delivery of infertility treatment services to different categories of beneficiaries. Beneficiaries may range in age from newborn infants up to adults. However, infertility treatment services are not provided either until the beneficiaries reach childbearing age or until the policies of adult beneficiaries vest over a designated time period. Adults can purchase infertility insurance naming their infant child as beneficiary and pay premiums over time until the child reaches childbearing age. Once the child reaches childbearing age, the insurance policy can be utilized by the beneficiary or can be transferred.

The invention discloses a cervical contraceptive device containing a sperm-killing traditional Chinese medicine polygala, which comprises a circular tube support. The tube wall of the circular tube support has two layers. It is a methyl vinyl silicone rubber layer, the thickness of the methyl vinyl silicone rubber layer is 0.5-1 mm, the first fixed ring is set at one end of the round tube bracket, the second fixed ring is set at the other end of the round tube bracket, and the round tube bracket The Chinese medicine Polygala slow-release medicine suppository is installed inside, and the Chinese medicine Polygala slow-release medicine suppository is bullet-shaped, and a gap is set between its peripheral wall and the inner wall of the methyl vinyl silicone rubber layer, and the outer end of the second fixing ring is connected to the outer wall of the circular tube bracket. Install the medicine suppository fixing net at the junction. The structural design of the present invention is reasonable, and 265 cases of women of childbearing age have been clinically used for 3 years, and the statistics show that no shedding, displacement, bleeding, infection, backache, abdominal drop, and embedding into the uterine muscle wall have been found. The contraceptive device of the present invention provides a contraceptive device that is safe and reliable to use and has no side effects and complications for women of childbearing age.

The invention provides an in-vitro cultivation method of embryonic cells of mammals, especially humans, wherein quercetin is added into a culture medium. The invention also provides culture medium for embryonic cells of mammals, especially humans, containing quercetin. The in-vitro culture method and culture medium provided by the invention are particularly suitable for culturing embryo cells of mammals of middle or high childbearing age, including female humans.

Beneficiaries are registered by an insurance provider for an insurance coverage policy for fertility diagnosis and treatable infertility conditions using either manual or online registration applications over a communications network. Using, knowledge base systems, prospective beneficiary personal descriptor information is matched with terms and conditions information preloaded into the insurance company computer system to generate a customized contract for delivery of infertility treatment services to different categories of beneficiaries. Beneficiaries may range in age from newborn infants up to adults. However, infertility treatment services are not provided either until the beneficiaries reach childbearing age or until the policies of adult beneficiaries vest over a designated time period. Adults can purchase infertility insurance naming their infant child as beneficiary and pay premiums over time until the child reaches childbearing age. Once the child reaches childbearing age, the insurance policy can be utilized by the beneficiary or can be transferred.

The invention belongs to the field of traditional Chinese medicines and provides a traditional Chinese medicine composition with the functions of clearing heat and removing dampness and treating myoma of uterus. The composition mainly comprises the following traditional Chinese medicine ingredients by weight: 10-15g of forsythia, 10-15g of seaweeds, 10-15g of betel nuts, 3-8g of akebiaquinata, 3-8g of gardenia, 3-8g of rhizoma sparganii, 3-8g of peppermint, 3-8g of costustoot, 3-8g of golden cypress and 3-8g of green tangerine peel. The composition has the functions of clearing heat and removing dampness, promoting qi and activating blood circulation and softening hardness to diminish swelling and has a higher curative effect on symptomatically treating the women of childbearing age with myoma of uterus.

The invention relates to the field of health management, in particular to a traditional Chinese medicine pre-pregnancy health management system and method. The system comprises a data acquisition subsystem, a health service subsystem and a data management subsystem, wherein the data acquisition subsystem is used for carrying out data acquisition on user data and transmitting the data to the healthservice subsystem, and the user data comprises age, body temperature and headwords; the health service subsystem analyzes and evaluates the data and formulates health plans and schemes or provides consultation; the data management subsystem is used for storing the collected data, the health plans and the schemes, and is also used for tracking and predicting health conditions of users. The invention provides the traditional Chinese medicine pre-pregnancy health management system and method for women. Through traditional Chinese medicine identification of the pre-pregnancy health conditions ofwomen of childbearing age, the risk of adverse pregnancy outcomes is evaluated, and traditional Chinese medicine pre-pregnancy conditioning schemes are given with pertinence.

The cervical mucus detector for women of childbearing age of the present invention is a detection device for women of childbearing age to judge ovulation period and fertility through the detection of cervical mucus. The structure of the cervical mucus detector is a kind of open-mouth pliers. When it is closed, its head is equipped with a three-way sampler, a cup-shaped sampler, groove adsorption samplers on both sides, and a circular groove film sampling device on the upper and lower sides of the head. The above four sampling methods make it easy to insert into the vagina to collect cervical mucus samples with different properties in different periods in the menstrual cycle. After collecting the sample, open the mouth of the cervical mucus detector to observe its various physical properties: sampling volume, color, viscosity, transparency, fluidity and stringing characteristics, etc., so that women can judge the status of fertility by themselves and judge whether they are in Infertile or fertile period, etc., so as to achieve the purpose of contraception or conception.

The invention discloses a preparation method of duck astrovirus type I yolk antibody, which comprises the following steps: (1) using duck astrovirus type I inactivated vaccine to immunize breeding-aged hens to obtain highly immune eggs; (2) collecting High-free egg yolk, remove the yolk membrane and frenulum, and use a colloid mill to crush it to obtain egg yolk; (3) Mix the egg yolk obtained in step (2) with purified water at a volume ratio of 1:1 to 3, and stir evenly Finally, add citric acid with a final concentration of 0.8-2.5% weight-volume ratio and 2-4% polyanionic cellulose, stir well, place at 1-5°C for 3-6 hours, centrifuge at 1-5°C, and collect the supernatant; (4) Filter and sterilize the supernatant collected in step (3) to obtain egg yolk antibody liquid. The preparation method of duck astrovirus type I yolk antibody disclosed by the invention has simple steps, high efficiency and yield, less addition, and is economical and applicable.

The invention discloses a traditional Chinese medicinal composition for female pre-pregnancy conditioning. The traditional Chinese medicinal composition is prepared according to the following step: weighing radix bupleuri, angelica, ligusticum wallichii, rhizoma cyperi, dodder, suncured ginseng and golden cypress in parts by weight. The traditional Chinese medicinal composition can significantly increase the pregnancy rate of women of childbearing age, and is good in therapeutic effect and free of toxic and side effects; raw materials are easy to obtain; a preparation method is simple and easyto implement.

The invention discloses a specific methylation detection primer and a diagnostic kit for endometriosis, and relates to the field of biotechnology. According to the SF-1 gene in the endometriosis genome, the present invention designs PCR amplification primers and related kits for endometriosis-specific methylation detection. Use the primers and kit to perform PCR amplification on the sample DNA modified by bisulfite to be tested, obtain the methylation site information of the SF-1 gene according to the sequencing results of the amplified products, and judge according to the methylation site information Whether the sample to be tested is a sample of a patient with endometriosis, so as to realize the diagnosis of endometriosis. The primer or kit provided by the present invention can be used to diagnose endometriosis objectively, sensitively and stably at an early stage, so as to perform timely and targeted treatment and improve the quality of life of women of childbearing age.

The invention relates to a method and composition for use in treating a condition that benefits from the reduction of hepatic and / or visceral fat, such as polycystic ovary syndrome in adolescent girlsor women of childbearing age, involving the use of spironolactone, pioglitazone and metformin.

The invention relates to a method for establishing a mammary gland bioreactor. The method is to introduce a target gene into the mammary duct or mammary gland tissue of an animal through a transfection solution, so that the target gene is expressed in the mammary gland under the control of a milk protein-specific regulatory sequence, It is characterized in that stem cell supporting factors are added to the transfection solution; the transfection solution containing the target gene is introduced in the animal's sexual development period or sexual maturity period or early pregnancy or weaning period to transfect mammary gland stem cells in the animal body. The establishment method of the mammary gland bioreactor of the present invention not only has a high success rate (50%-80%), low difficulty in operation, short production cycle and low cost, but also can be used repeatedly during the reproductive age of animals, and has a high commercial value.